While HER2 and αVβ6 integrin are independent prognostic indicators in breast cancer, patients with HER2+ breast cancer and high αVβ6 expression exhibit reduced survival compared with patients with low αVβ6 expression (17). Here, ERBB2 is linked to breast carcinoma.